Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$18.05
+2.3%
$14.76
$9.60
$19.09
$2.37B1.481.14 million shs1.28 million shs
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$73.72
+0.3%
$69.63
$61.40
$87.77
$4.37B1.22406,618 shs299,598 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.55
-5.9%
$2.75
$1.83
$7.48
$2.56B0.129.17 million shs9.76 million shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.94
$2.60
$1.05
$3.31
$631.10M0.982.85 million shs2.89 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
+2.32%+6.05%+15.34%+44.28%+43.25%
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
+0.37%+3.60%+6.90%+4.39%+4.76%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-5.90%+4.51%-7.27%-10.21%-34.28%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%+8.09%+15.75%+8.89%+27.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.6107 of 5 stars
3.51.00.00.02.23.30.6
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.2696 of 5 stars
1.34.00.00.03.33.31.3
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.2591 of 5 stars
3.61.00.00.02.41.70.6
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.4935 of 5 stars
4.52.00.00.02.93.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$28.1055.68% Upside
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.67
Moderate Buy$80.338.97% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$10.75321.57% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.29181.83% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, IBRX, and CNTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00
8/13/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.50 ➝ $8.00
8/12/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
8/12/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
8/5/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/30/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/25/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/21/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
7/11/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
7/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/1/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$6.85M353.28N/AN/A$2.57 per share7.02
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$1.75B2.50$9.73 per share7.58$47.55 per share1.55
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M163.53N/AN/A($0.60) per share-4.25
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M75.76N/AN/A$1.16 per share2.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%N/A
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$200.55M$4.5716.1380.13N/A12.85%10.51%3.15%N/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%N/A

Latest TSHA, HHH, IBRX, and CNTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A
8/12/2025Q2 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million
8/5/2025Q2 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.32
10.11
14.37
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
1.85
1.18
1.41
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.11
3.98
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.17
12.48
5.35

Institutional Ownership

CompanyInstitutional Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
93.83%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
7.09%
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
33.00%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200134.07 million124.57 millionOptionable
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
60859.40 million39.80 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590945.26 million219.39 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable

Recent News About These Companies

FY2025 EPS Forecast for Taysha Gene Therapies Cut by Analyst
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00
Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results
What's Next: Taysha Gene Therapies's Earnings Preview
Taysha Gene Therapies Advances Rett Syndrome Trials
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$18.05 +0.41 (+2.32%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$18.04 -0.02 (-0.08%)
As of 08/15/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Howard Hughes stock logo

Howard Hughes NYSE:HHH

$73.72 +0.23 (+0.31%)
Closing price 08/15/2025 03:58 PM Eastern
Extended Trading
$74.16 +0.44 (+0.59%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.55 -0.16 (-5.90%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.56 +0.01 (+0.43%)
As of 08/15/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.94 0.00 (0.00%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.94 0.00 (-0.17%)
As of 08/15/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.